Potential biomarkers emerge for 177Lu-PSMA-617 in metastatic prostate cancer
November 14th 2022177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.